CRISPR and beyond – perturbations at scale to understand genomes
Wellcome Genome Campus, Hinxton, Cambridge, CB10 1RQ, UK
For more information and to register click here.
Submit your abstract here, deadline 9th July 2019.
Large scale genome sequencing has led to deep catalogues of natural and disease-related human genetic variation. Unfortunately, we do not understand the functional implications of the vast majority of detected variants, and therefore cannot use them for healthcare or research. The rapid advances of CRISPR/Cas-based technologies and DNA synthesis now make it possible to modulate genomes with relative ease. These tools can help us understand how genetic variation impacts phenotype and answer important long-standing questions in biology that also impact human health, laying the foundations for precision medicine for heritable diseases and cancer treatment.
The programme will cover approaches that modulate the genome and its context at scale, from single nucleotides and genes to hundreds of growth environments. The conference will bring together biomedical researchers working on high throughput screening, genome engineering, and/or variant effect interpretation. We welcome abstracts on all major themes of this meeting to oral or poster presentations.
Britt Adamson – University of Princeton, USA
Brenda Andrews – University of Toronto, Canada
Michael Boutros – DKFZ Heidelberg, Germany
Ellen Bushell – Umea University, Sweden
Ulrich Elling – Institute of Molecular Biology, Austria
Douglas Fowler – Unversity of Washington, USA
Molly Gasperini – University of Washington, USA
Maya Ghoussaini – OpenTargets, UK
Luke Gilbert – UCSF, USA
Emma Haapaniemi – University of Oslo, Norway
Ben Lehner – Centre for Genomic Regulation, Spain
James McFarland – Broad Institute, USA
Fritz Roth – University of Toronto, Canada
Jussi Taipale – University of Cambridge, UK
Sibylle Vonesch – EMBL, Germany
Yanli Wang – Institute of Biophysics CAS, China